Current Appointments & Affiliations
Assistant Professor of Neurology
·
2021 - Present
Neurology, Neuromuscular Disease,
Neurology
Co-Medical Director of Duke Clinical Research at Pickett Road
·
2022 - Present
Neurology,
Clinical Science Departments
Faculty Director of Duke Early Phase Research Unit
·
2022 - Present
Neurology,
Clinical Science Departments
Recent Publications
COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey.
Journal Article Muscle Nerve · October 2025 INTRODUCTION/AIMS: Patients with myasthenia gravis (MG) often receive immunosuppressive treatments. While approved COVID-19 vaccines effectively prevent severe infections, the impact of vaccination among immunocompromised MG patients remains unclear. This ... Full text Link to item CiteSensitivity of Repetitive Nerve Stimulation Performed in Early and Later Stages of Myasthenia Gravis.
Journal Article Muscle Nerve · October 2025 INTRODUCTION/AIMS: Repetitive nerve stimulation (RNS) is a valuable tool in the diagnostic evaluation of myasthenia gravis (MG). However, there are conflicting reports of its sensitivity when performed ≤ 30 days from symptom onset. We aim to compare the se ... Full text Link to item CiteA Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers.
Journal Article Clin Pharmacol Ther · November 2024 (R,S)-Ketamine (ketamine) is a dissociative anesthetic that also possesses analgesic and antidepressant activity. Undesirable dissociative side effects and misuse potential limit expanded use of ketamine in several mental health disorders despite promising ... Full text Link to item CiteRecent Grants
A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients with Early Symptomatic AD
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2035DNA09-A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Immunovant · 2025 - 2034A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients with Early Symptomatic Alzheimer's Disease
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2029View All Grants
Education, Training & Certifications
Thomas Jefferson University ·
2011
M.D.